


## IN THE CLAIMS

Please add Claims 36-48:

--36. (New) A compound of the general formula (I):



wherein

$R^1$  is aryl which may have one or more suitable substituent(s), heterocyclic group or cyclo(lower)alkyl,

$R^2$  is hydrogen or amino protective group,

$R^3$  and  $R^4$  are independently hydrogen, halogen, hydroxy, amino, nitro, carboxy, protected carboxy, aryl, lower alkyl, hydroxy(lower)alkyl, amino(lower)alkyl, acyloxy(lower)alkyl, acylamino(lower)alkyl, lower alkylamino(lower)alkyl which may have one or more suitable substituent(s), mono or di-(lower)alkylamino, acylamino, acyl group, lower alkoxy, halo(lower)alkoxy, lower alkenyloxy, lower alkoxy(lower)alkoxy, aryloxy, cyclo(lower)alkyloxy, heterocycloxy, ar(lower)alkyloxy, acyloxy, lower alkylcarbamoyl(lower)alkoxy, heterocycliccarbamoyl(lower)alkoxy, heterocycliccarbonyl(lower)alkoxy, N-lower alkyl-lower alkylcarbamoyl(lower)alkoxy, arylcarbamoyl(lower)alkoxy which may have lower alkoxy or di(lower)alkylamino, di-lower alkylsulfamoyloxy, N-lower alkyl-heterocyclic(lower)alkylcarbamoyl(lower)alkoxy, N-lower alkyl-lower alkylcarbamoyl(lower)alkoxy or N-lower alkyl-cyclo(lower)alkylcarbamoyl(lower)alkoxy,

# COPY

R<sup>5</sup> is hydrogen, lower alkyl, or aryl,

A is lower alkylene which may have one or more suitable substituent(s) or lower alkenylene,

X is O, S, SO, SO<sub>2</sub> or NH, and

m is an integer of 0 or 1,

or a salt thereof,

wherein when R<sup>1</sup> is naphthyl and R<sup>5</sup> is H, then X is not O.

37. (New) The compound of claim 36, wherein

R<sup>1</sup> is phenyl which may have 1 or 2 suitable substituent(s) selected from the group consisting of hydroxy and lower alkylsulfonylamino,

R<sup>2</sup> is hydrogen,

R<sup>3</sup> is lower alkylcarbamoyl(lower)alkoxy, heterocycliccarbamoyl(lower)alkoxy, heterocycliccarbonyl(lower)alkoxy, N-lower alkyl-lower alkylcarbamoyl(lower)alkoxy, hydroxy, lower alkoxy, protected carboxy, arylcarbamoyl(lower)alkoxy which may have lower alkoxy or di(lower)alkylamino, di-lower alkylsulfamoyloxy, N-lower alkyl-heterocyclic(lower)alkylcarbamoyl(lower) alkoxy, N-lower alkyl-lower alkylcarbamoyl(lower)alkoxy or N-lower alkyl-cyclo(lower)alkylcarbamoyl(lower)alkoxy,

R<sup>4</sup> is hydrogen,

R<sup>5</sup> is hydrogen,

A is lower alkylene,

X is O, and

m is an integer of 1.--


38. (New) The compound of claim 37, wherein

R<sup>1</sup> is phenyl which may have hydroxy and methylsulfonylamino,


$R^3$  is ethylcarbamoylmethoxy, indolylcarbamoylmethoxy, piperidinocarbonylmethoxy, N-methylbutylcarbamoylmethoxy, hydroxy, butylcarbamoylmethoxy, methoxy, methoxycarbonyl, ethoxy, dimethylsulfamoyloxy, tetrazolylcarbamoylmethoxy, N-methylpyridylethylcarbamoylmethoxy, methoxyphenylcarbamoylmethoxy, thiazolylcarbamoylmethoxy, dihydroindolylcarbonylmethoxy, N-ethylpropylcarbamoylmethoxy, N-methylbutylcarbamoylmethoxy, N-ethylbutylcarbamoylmethoxy, dimethylaminophenylcarbamoylmethoxy or N-methylcyclohexylcarbamoylmethoxy.

39. (New) A process for preparing a compound of claim 36, or a salt thereof, which comprises,

(i) reacting a compound (II) of the formula:




wherein  $R^1$ ,  $R^5$ , A, X and m are each as defined in claim 36, with a compound (III) of the formula:




wherein  $R^2$ ,  $R^3$  and  $R^4$  are each as defined in claim 36, or a salt thereof, to give a compound (I) of the formula:

**COPY**




wherein  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ , A, X and m are each as defined in claim 36, or a salt thereof, or

(ii) subjecting a compound (Ia) of the formula:



wherein  $R^1$ ,  $R^3$ ,  $R^4$ ,  $R^5$ , A, X and m are each as defined in claim 36, and

$R_a^2$  is amino protective group, or a salt thereof, to elimination reaction of the amino protective group, to give a compound (Ib) of the formula:



wherein  $R^1$ ,  $R^3$ ,  $R^4$ ,  $R^5$ , A, X and m are each as defined in claim 36, or a salt thereof.

40. (New) A pharmaceutical composition which comprises the compound of claim 36 or a pharmaceutically acceptable salt thereof in admixture with a pharmaceutically acceptable carrier or excipient.

41. (New) A method for making a pharmaceutical composition or a medicament comprising admixing the compound of claim 36 or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable carrier or excipient.

42. (New) A compound of claim 36 or a pharmaceutically acceptable salt thereof in the form of a tablet, pellet, troche, capsule, suppository, cream, ointment, aerosol, powder for insufflation, solution, emulsion, or suspension.

43. (New) A method for the prophylactic and/or the therapeutic treatment of pollakiuria or urinary incontinence which comprises administering an effective amount of a compound of claim 36 or a pharmaceutically acceptable salt thereof to a subject in need thereof.--

44. (New) A method for agonizing a  $\beta_3$  adrenergic receptor comprising contacting said receptor with the compound of claim 36.

45. (New) A method for inducing gut-selective sympathomimetic activity comprising administering an effective amount of the compound of claim 36 to a subject in need thereof.

46. (New) A method for the prophylactic and/or the therapeutic treatment of a gastrointestinal disorder comprising administering an effective amount of the compound of claim 36 or a pharmaceutically acceptable salt thereof to a subject in need thereof.

47. (New) A method for the prophylactic and/or the therapeutic treatment of an ulcer or pancreatitis comprising administering an effective amount of the compound of claim 36 or a pharmaceutically acceptable salt thereof to a subject in need thereof.

48. (New) A method for inducing lypolysis comprising administering an effective amount of the compound of claim 36 or a pharmaceutically acceptable salt thereof to a subject in need thereof.----